# Legacy Software Validation in Clinical Trials: A Practical Step-by-Step Path to FDA SaMD Compliance

Obsolete code quietly powers more clinical trials than most sponsors care to admit. From laboratory systems that predate modern integration standards to electronic data capture platforms maintained by a single retiree-to-be, legacy software remains the backbone of many studies. For teams facing this reality, the step-by-step validation for obsolete code under FDA SaMD guidance is not just a regulatory exercise—it is the difference between study continuity and costly interruption. The good news? You don’t need to rewrite the system. You need to build a validation story that satisfies regulators using the evidence you already have, plus a few targeted gaps.

Why Legacy Systems Still Run Clinical Trials

Legacy software persists in clinical research for three reasons: cost, stability, and fear of disruption. Replacing a validated system that has been collecting clean data for a decade introduces integration risk, user retraining costs, and potential data migration errors. Meanwhile, the system keeps working. The result is a sprawling landscape of old code embedded in modern workflows, often connected through fragile middleware and manual workarounds.

Regulators understand this. They do not expect every trial to run on bleeding-edge platforms. But they do expect sponsors to demonstrate that any software used in a clinical trial—regardless of age—remains fit for its intended purpose. The challenge is that many legacy systems were validated under earlier expectations, using documentation standards that no longer align with current FDA SaMD-supervised thinking.

The Regulatory Reality Check for Obsolete Code

Under the FDA’s Software as a Medical Device guidance, the depth of validation must match the level of risk associated with the software. That concept applies to clinical trial software too, especially when the software is used in regulatory submissions. The key shift in recent years is the emphasis on a total product lifecycle approach: the FDA expects evidence that the software is safe, effective, and secure not just on day one, but throughout its operational life.

For obsolete code, this creates a dilemma. Original design documentation may be scattered, incomplete, or held by a vendor that no longer exists. The good news is that the SaMD framework allows for alternative evidence. Functional testing, real-world performance data, and controlled retrospective analysis can compensate for missing design records—provided you approach the validation systematically.

The Step-by-Step Validation Framework for Legacy Software

This six-step framework is designed to produce a defensible validation package without forcing a full rewrite of your existing system. It aligns with the risk-based principles of FDA SaMD guidance while remaining practical for teams working with limited original documentation.

Step 1: Inventory and Criticality Classification

Before you can validate anything, you need to know exactly what you have. Create a comprehensive inventory of every software system used in the study, including the version number, date of deployment, purpose, data flow, and user roles. Then classify each system by its impact on subject safety and data integrity.

Systems that directly influence dosing decisions, adverse event detection, or primary endpoint calculations require the most rigorous evidence. Systems that play a peripheral role, like simple scheduling tools, can be addressed with lighter documentation. This classification drives the entire validation effort and prevents you from wasting resources on low-risk utilities.

Step 2: Requirements Gap Analysis

Next, map the system’s current functionality against contemporary user requirements and regulatory expectations. Identify where the original design specifications are missing or outdated. This gap analysis should also consider recent FDA expectations around data integrity, audit trails, and cybersecurity.

You may find that the software meets most requirements but lacks a feature like role-based access control. Or you may discover that the audit trail exists but is only visible to a system administrator. Document every gap. You will decide in the next step which gaps require fixing and which can be justified as acceptable given the risk profile and available mitigation controls.

Step 3: Risk-Based Evidence Collection

This is where you gather the evidence to support your validation claims. For legacy software, the most compelling evidence often comes from operational history. If the system has been running in the same configuration for years, you can use that real-world performance data as evidence of reliability.

• Historical validation documents: Retrieve any original IQ/OQ/PQ protocols, test scripts, and release notes. Even partial records can be valuable.
• Change and incident logs: Compile the system’s change history, bug fixes, and reported incidents. A documented pattern of stable operation is powerful evidence.
• Regression and targeted testing: Run focused tests on high-risk functions that directly affect subject safety or data integrity. These tests do not need to replicate the entire original test suite—they should target the critical requirements identified in Step 2.
• User feedback and SOP compliance: Collect evidence that operators are trained, procedures are followed, and any workarounds are controlled and documented.

Weigh each piece of evidence against the level of risk. High-risk items need stronger, more current evidence. Low-risk items can often be supported by historical data and standard operating procedure compliance reviews.

Step 4: Control Implementation and Defect Handling

Once evidence collection is complete, address the material gaps that remain. Implementing a full redesign is rarely necessary. Instead, consider administrative controls, interface wrappers, or middleware that add the missing capabilities. For example, if the legacy system lacks a compliant audit trail, you can implement an external logging layer that captures all user actions at the application level.

Establish a clear defect-handling process before validation is considered complete. Define how bugs will be reported, prioritized, fixed, and re-tested. If the source code is unavailable or the vendor is defunct, document a workaround procedure and ensure that known limitations are listed in the system’s risk assessment. The goal is to show that you are managing the software’s limitations rather than ignoring them.

Step 5: Documentation and Traceability Matrix

Regulators need to see a clear thread that connects each requirement to its evidence. Build a traceability matrix that maps every identified requirement to the specific document, test case, or operational record that satisfies it. This artifact becomes the centerpiece of your validation package.

Write the validation report in plain language. Describe the system, its intended use, the risk assessment, and the evidence collected. For any requirement that could not be fully verified, explain why and document the accepted risk. A transparent report that acknowledges limitations is far more credible than a flawless-looking document that hides gaps.

Step 6: Ongoing Monitoring and Retirement Planning

Validation is not a one-time event. Establish a periodic review cycle under the SaMD total product lifecycle approach. Monitor system performance, review incident logs, and reassess the risk profile each time the surrounding environment changes—for instance, when the system is integrated with a new EDC platform or exposed to new security threats. Also create a realistic retirement plan. Identify the steps needed to migrate data and decommission the system, so the validation is seen as part of an intentional lifecycle rather than an endless deferral.

Common Pitfalls That Derail Legacy Validation Projects

Even with a clear framework, validation projects fail when teams make familiar mistakes. The most common one is treating the process as a documentation exercise rather than an evidence-building effort. Another is over-testing low-risk functions while ignoring the high-risk workflows that matter most to the study. Also, teams often underestimate how long it takes to locate archival evidence. Start the search early, and keep a living log of where every document lives.

Finally, do not expect perfection. Legacy software will always carry some level of residual risk. The FDA accepts that, provided you can articulate the risk, support your rationale, and demonstrate that you are controlling it. A validation package that is honest about limitations is more useful than one that hides them behind clever wording.

Building a Sustainable Validation Culture

The best time to deal with legacy software is before the next audit, not during it. The second-best time is right now. By adopting this step-by-step approach, you turn obsolete code from a regulatory liability into a documented, controlled asset. The same evidence that satisfies an FDA inspector also gives your study teams clarity about what the system can and cannot do, which reduces data errors and operational surprises down the line.

As more trial sponsors move toward decentralized and real-world data sources, the pressure to modernize will only grow. But the path forward does not require abandoning every legacy tool. It requires applying modern validation reasoning to the systems that still anchor your studies.

Conclusion

Legacy software will remain a fixture in clinical trials for years to come. With a risk-based, step-by-step validation process aligned with FDA SaMD guidance, sponsors can bring obsolete code into compliance without disruptive rewrites. The key is to shift the mindset from “prove everything is perfect” to “demonstrate that the system is fit for its purpose, its risks are understood, and its limitations are controlled.” That shift is both pragmatic and inspection-ready.